Effect of antidiabetic drug on endothelial function - EFFORT
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 40
研究概览
简要总结
The RH-PAT and laboratory parameters, including 75 g oral glucose tolerance test, were measured at baseline and 3 months. Linagliptin reduced serum levels of glucose and insulin at 2 hours, and increased levels of active glucagon-like peptide-1 and high-molecular-weight adiponectin. Age-, sex-, and baseline-adjusted changes in logarithmic RH-PAT index (LnRHI) after 3 months were significant between groups (linagliptin, 0.135±0.097; voglibose, -0.124±0.091; P=0.047). In the linagliptin group, change in LnRHI was positively correlated with change in high-density lipoprotein cholesterol and negatively correlated with changes in both urine albumin-to-creatinine ratio and high-sensitivity C-reactive protein.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients with liver disease (ALT or AST level is over 100IU/L, total Bil level is over 2.5mg/dl). 2. Patients with congenital heart disease. 3. Patients with highly advanced cardiac dysfunction. 4. Patients with endocrine disease. 5. Patients with malignancy or inflammatory disease. 6. Patinets with highly advanced respiratory disease (containing pulmonary arterial pulmonary hypertension. 7. Patients with cranial nerve disease or locomotor apparatus disease, and severely compromised daily life. 8. Patients with severe hypertension. 9. Patients administrated steroid or immune suppressor. 10. Patients with type1 DM or type2 DM and HbA1c (NGSP) 6.5% or more. 11. Patients during pregnancy or with possibility of pregnancy. 12. Patients administrated catecholamine. 13. Patients with symptomatic hypotension. 14. Patients with significant LVOT obstruction (Hypertrophic obstructive cardiomyopathy or aortic stenosis). 15. Patients without written consent. 16. Patients recognized inadequate by primary doctor.
